Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01772719 · ClinicalTrials.gov registry record · NA
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
A NA study, sponsored by University of Louisville.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT01772719 is a NA study that was terminated before completion, run by University of Louisville. The registered enrollment target is 7 participants.
The verdict
NCT01772719, a NA study, was terminated before completion, sponsored by University of Louisville.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of simvastatin and zoledronic acid on M-protein and/or free light chains when added to conventional chemotherapy for the treatment of multiple myeloma patients.
Interventions
- DRUG Simvastatin and zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01772719
The ClinicalTrials.gov registry entry for NCT01772719 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Simvastatin and zoledronic acid is the first listed.
NCT01772719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01772719 about?
NCT01772719 is a clinical study titled "Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid". The purpose of this study is to examine the effect of simvastatin and zoledronic acid on M-protein and/or free light chains when added to conventional chemotherapy for the treatment of multiple myeloma patients.
What is the current status of trial NCT01772719?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2012-08. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01772719?
The interventions under investigation include: Simvastatin and zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT01772719?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.